Liver, kidney (renal cell carcinoma), and germ cell tumors are rare cancer diagnoses in children and adolescents (Ward E., et al 2014). Enrollment on clinical trials is essential for the continued improvements in outcomes for children with cancer; however, uncommon childhood malignancies make the conduct of these trials a significant challenge (Czauderna P., et al 2016).
Pediatric oncology nurses will encounter very few patients with these unique diagnoses and therefore need to develop strategies to deliver precise protocol-directed care. This session will provide a brief overview of the latest Children’s Oncology Group (COG) intergroup collaborative clinical trials for some of these rare tumors in children. The Pediatric Hepatic Malignancy International Therapeutic Trial (AHEP1531), the Renal Cell Carcinoma Trial (AREN1721), and the Intermediate and Poor-Risk Metastatic Germ Cell Tumor Trial (AGCT1532) will be discussed. A brief overview of each trial, including the clinical background, eligibility, and treatment, will be described. There will be specific emphasis on nursing considerations unique to each trial, new agents, and drug combinations. Examples of patient and nursing experiences from these trials will be shared, highlighting clinical implications, to better prepare the nurse to deliver protocol-directed therapy to children enrolled on rare tumor COG trials.
- Closing Keynote: Why We Chose Nursing and How Nursing Continues to Choose Us (104)
- General Session: Nursing Emotional IQ (103)
- General Session: Controversies and Conundrums in the Use of Opioids in AYAs with Cancer (102)
- Opening Keynote: The American Nurse: Stories of Life-Changing Impact (101)
- Paper Presentation: Education Across the Cancer Care Continuum — Evidence-Based Interprofessional Palliative Care Education: Lessons for Pediatric Oncology Clinicians (204-2)